UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Preinitiation
Unique ID issued by UMIN UMIN000004374
Receipt No. R000005230
Scientific Title Identification of serum markers mediating resistance to sunitinib in patients with renal cell carcinoma
Date of disclosure of the study information 2010/10/13
Last modified on 2010/10/12

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Identification of serum markers mediating resistance to sunitinib in patients with renal cell carcinoma
Acronym Identification of serum markers mediating resistance to sunitinib in patients with renal cell carcinoma
Scientific Title Identification of serum markers mediating resistance to sunitinib in patients with renal cell carcinoma
Scientific Title:Acronym Identification of serum markers mediating resistance to sunitinib in patients with renal cell carcinoma
Region
Japan

Condition
Condition renal cell carcinoma
Classification by specialty
Urology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 The objective of this study is to identify serum markers associated with resistant phenotype to sunitinib in patients with metastatic RCC in order to develop the precise system for predicting the probability of the acquired resistant phenotype to sunitinib in patients with RCC during treatment with this agent.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes  Before and during treatment with sunitinib, measure serum levels of several molecules (E-cadherin, N-cadherin, fibronectin, MMP-2, MMP-3, MMP-9, MT-MMP-1, TIMP-1, TIMP-2, clusterin, bFGF, uPA and uPAR), which have been shown to be regulated by activated p44/42 MAPK and Akt and to be involved in the acquisition of an EMT phenotype in our preliminary experiments, in patients with metastatic RCC by sandwich enzyme-linked immunosorbent assay (ELISA) kits.
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria Histologically confirmed metastatic RCC with a component of clear cell histology.

Presence of measurable disease; that is, at least 1 metastatic tumor mass that can be accurately measured in at least 1 dimension over 10 mm with conventional radiological modalities, such as computed tomography and magnetic resonance imaging.



Age of over 20 years.

ECOG performance status of 0 or 1.
Life expectancy of over 12 weeks
Key exclusion criteria Prior use of sunitinib

Seizure disorder, evidence of brain metastases, spinal cord compression or carcinomatous meningitis.

Active bacterial, fungal or viral infection.

History of malignancy other than RCC except for those treated with curative intent with no evidence of disease for at least 2 years.

Other severe acute or chronic medical condition.
Target sample size 100

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Masato Fujisawa
Organization Kobe University Graduate school of Medicine
Division name Department of Urology
Zip code
Address 7-5-1,Kusunoki-tyo,Kobe-city, Japan
TEL
Email

Public contact
Name of contact person
1st name
Middle name
Last name
Organization Kobe University Graduate school of Medicine
Division name Department of Urology
Zip code
Address 7-5-1,Kusunoki-tyo,Kobe-city, Japan
TEL
Homepage URL
Email

Sponsor
Institute Kobe University Graduate school of Medicine
Institute
Department

Funding Source
Organization pfizer pharmacology
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2010 Year 10 Month 13 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Preinitiation
Date of protocol fixation
2010 Year 09 Month 10 Day
Date of IRB
Anticipated trial start date
2010 Year 11 Month 01 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information not finished

Management information
Registered date
2010 Year 10 Month 12 Day
Last modified on
2010 Year 10 Month 12 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005230

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.